Synthesis of Improved Antileishmanial and Antitrypanosomal Drugs Treatment and Prophylaxis

The program is directed at the preparation of improved antileishmanial and antitrypanosomal drugs. During the past year 13 target compounds were submitted for testing against L. donovani, T. rhodesiense and T. cruzi. Two candidate antileishmanials are modified 8-aminoquinolines. Eleven compounds were directed primarily against T. cruzi. These included seven 2,2- di(or tri)aryldimethyl(or dihydro)aminomethylethylenes and four 1-amidoximino-2, 2-di(or tri)diarylethylenes.